ClinicalTrials.gg
CompletedNCT03460990Updated Oct 17, 2019Results posted

A Study of VX-659 Combination Therapy in CF Subjects Homozygous for F508del (F/F)

A Phase 3 interventional study of VX-659/TEZ/IVA and TEZ/IVA in Cystic Fibrosis, sponsored by Vertex Pharmaceuticals Incorporated. Completed at 46 sites in 6 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2019-10-17.

Sponsored by Vertex Pharmaceuticals Incorporated · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
116
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 125 studies in Cystic Fibrosis by Vertex Pharmaceuticals Incorporated — 3 open to participants now, 8 under way, 5 of them phase 3. Cystic Fibrosis · Vertex Pharmaceuticals Incorporated.

Enrollment
44th of 116
116 · median 73
Started
2018
with 12 others
Phase 3
62 of 125
1 open now
Registered
72nd of 125
by date

Among the 125 studies in Cystic Fibrosis by Vertex Pharmaceuticals Incorporated, this one is the 44th largest by enrollment of the 116 interventional ones that give a count, is one of 13 that started in 2018, is one of 62 in phase 3, and was the 72nd registered.

Cystic Fibrosis

1,621 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.

Browse Cystic Fibrosis studies →

Open to participants now

3 of the 125 studies in Cystic Fibrosis by Vertex Pharmaceuticals Incorporated are open now, in 10 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 86 take children under 18; 41 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 125 studies in Cystic Fibrosis by Vertex Pharmaceuticals Incorporated, or all of them as a file.
02

Study summary

This study will evaluate the efficacy of VX-659 in triple combination (TC) with tezacaftor (TEZ) and ivacaftor (IVA) in subjects with cystic fibrosis (CF) who are homozygous for the F508del mutation (F/F).

03

Conditions studied

  • Cystic Fibrosis

Browse trials for

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Homozygous for the F508del mutation (F/F)
  • (FEV1) value ≥40% and ≤90% of predicted mean for age, sex, and height

Key Exclusion Criteria:

  • cirrhosis with or without portal hypertension
  • Lung infection with organisms associated with a more rapid decline in pulmonary status
  • Solid organ or hematological transplantation

Other protocol defined Inclusion/Exclusion criteria may apply

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
116 participants (actual)

Study arms

  • Active comparator
    TEZ/IVA

    Following a run-in period of 4 weeks with Tezacaftor (TEZ)/Ivacaftor (IVA), participants received TEZ 100 milligram (mg)/IVA 150 mg as fixed-dose combination (FDC) tablet in the morning and IVA 150 mg as mono tablet in the evening for 4 weeks in the triple combination (TC) treatment period.

    Drug: TEZ/IVA · Drug: IVA · Drug: Placebo

  • Experimental
    VX-659/TEZ/IVA TC

    Following a run-in period of 4 weeks with TEZ/IVA, participants received VX-659 240 mg/TEZ 100 mg/IVA 150 mg as FDC tablets in the morning and IVA 150 mg as mono tablet in the evening for 4 weeks in the TC treatment period.

    Drug: VX-659/TEZ/IVA · Drug: IVA · Drug: Placebo

Interventions

  • DrugVX-659/TEZ/IVA

    Participants received VX-659/TEZ/IVA orally once daily in the morning.

    Also known as: VX-659/VX-661/VX-770, VX-659/tezacaftor/ivacaftor

  • DrugTEZ/IVA

    Drug pages: Tezacaftor · Ivacaftor

    Participants received TEZ/IVA orally once daily in the morning.

    Also known as: VX-661/VX-770, tezacaftor/ivacaftor

  • DrugIVA

    Participants received IVA orally once daily in the evening.

    Also known as: VX-770, ivacaftor

  • DrugPlacebo

    Participants received placebo matched TEZ/IVA orally once daily in the morning.

  • DrugPlacebo

    Participants received placebo matched to VX-659/TEZ/IVA orally once daily in the morning.

06

What researchers measure

Primary outcomes

  1. Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1)

    FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.

    Time frame: From Baseline at Week 4

Secondary outcomes

  1. Absolute Change in Sweat Chloride (SwCl)

    Sweat samples were collected using an approved collection device.

    Time frame: From Baseline at Week 4

  2. Absolute Change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score

    The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms, score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life.

    Time frame: From Baseline at Week 4

  3. Safety and Tolerability as Assessed Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Time frame: From first dose of study drug in TC treatment period up to 28 days after last dose of study drug or to the completion of study participation date, whichever occurs first (up to Week 8)

  4. Observed Pre-Dose Concentration (Ctrough) of VX-659, TEZ, TEZ Metabolite (M1-TEZ), and IVA

    Time frame: From Day 1 and Week 4

07

Results

Posted Oct 17, 2019

Participant flow

A total of 116 participants were enrolled in the study, of which 5 participants were included in the run-in period but were not dosed in TC treatment period. Results are presented for 111 participants dosed in the TC treatment period.

Participant flow — Overall Study
MilestoneTEZ/IVAVX-659/TEZ/IVA TC
Started5754
Completed5754
Not completed00

Outcome measures

PrimaryAbsolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1)

FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.

Time frame:
From Baseline at Week 4
Reported as:
Least squares mean · percentage points
Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1)
percentage pointsTEZ/IVAVX-659/TEZ/IVA TC
Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1)0.3 ± 0.910.2 ± 0.9
Statistical analysis
  • TEZ/IVA vs VX-659/TEZ/IVA TC · Mixed-effects model for repeated measure · p = < 0.0001 · Least squares (ls) mean difference: 10 · 95% CI 7.4 to 12.5
SecondaryAbsolute Change in Sweat Chloride (SwCl)

Sweat samples were collected using an approved collection device.

Time frame:
From Baseline at Week 4
Reported as:
Least squares mean · millimole per liter (mmol/L)
Absolute Change in Sweat Chloride (SwCl)
millimole per liter (mmol/L)TEZ/IVAVX-659/TEZ/IVA TC
Absolute Change in Sweat Chloride (SwCl)1.5 ± 1.8-47.2 ± 1.9
Statistical analysis
  • TEZ/IVA vs VX-659/TEZ/IVA TC · Mixed-effects model for repeated measure · p = <0.0001 · Ls mean difference: -48.7 · 95% CI -53.9 to -43.5
SecondaryAbsolute Change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score

The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms, score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life.

Time frame:
From Baseline at Week 4
Reported as:
Least squares mean · units on a scale
Absolute Change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score
units on a scaleTEZ/IVAVX-659/TEZ/IVA TC
Absolute Change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score3.0 ± 1.716.5 ± 1.7
Statistical analysis
  • TEZ/IVA vs VX-659/TEZ/IVA TC · Mixed-effects model for repeated measure · p = <0.0001 · Ls mean difference: 13.5 · 95% CI 8.8 to 18.3
SecondarySafety and Tolerability as Assessed Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
Time frame:
From first dose of study drug in TC treatment period up to 28 days after last dose of study drug or to the completion of study participation date, whichever occurs first (up to Week 8)
Reported as:
Number · participants
Safety and Tolerability as Assessed Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
participantsTEZ/IVAVX-659/TEZ/IVA TC
Participants with AEs3133
Participants with SAEs02
SecondaryObserved Pre-Dose Concentration (Ctrough) of VX-659, TEZ, TEZ Metabolite (M1-TEZ), and IVA
Time frame:
From Day 1 and Week 4
Reported as:
Mean · nanogram per milliliter (ng/mL)
Observed Pre-Dose Concentration (Ctrough) of VX-659, TEZ, TEZ Metabolite (M1-TEZ), and IVA
nanogram per milliliter (ng/mL)TEZ/IVAVX-659/TEZ/IVA TC
Week 4: VX-659—720 ± 589
Day 1: TEZ1780 ± 8321590 ± 1020
Week 4: TEZ1730 ± 8851280 ± 594
Day 1: M1-TEZ5170 ± 16204840 ± 1860
Week 4: M1-TEZ5010 ± 18104730 ± 1380
Day 1: IVA717 ± 616563 ± 400
Week 4: IVA722 ± 642401 ± 211

Adverse events

Collected over From first dose of study drug in TC treatment period up to 28 days after last dose of study drug or to the completion of study participation date, whichever occurs first (up to Week 8). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
TEZ/IVA0/57 (0%)0/57 (0%)19/57 (33.3%)
VX-659/TEZ/IVA TC0/54 (0%)2/54 (3.7%)23/54 (42.6%)
Most frequent serious events
Most frequent serious events
EventTEZ/IVAVX-659/TEZ/IVA TC
DepressionPsychiatric disorders0/571/54
Suicidal ideationPsychiatric disorders0/571/54
ConstipationGastrointestinal disorders0/571/54
Most frequent other events
Most frequent other events
EventTEZ/IVAVX-659/TEZ/IVA TC
Sputum increasedRespiratory, thoracic and mediastinal disorders0/579/54
Infective pulmonary exacerbation of cystic fibrosisInfections and infestations9/572/54
HeadacheNervous system disorders5/573/54
CoughRespiratory, thoracic and mediastinal disorders3/574/54
C-reactive protein increasedInvestigations0/574/54
DiarrhoeaGastrointestinal disorders0/574/54
Alanine aminotransferase increasedInvestigations2/573/54
Aspartate aminotransferase increasedInvestigations1/573/54

Baseline characteristics

Age, Continuous
Age, Continuous(years)TEZ/IVAVX-659/TEZ/IVA TCTotal
Mean26.2 ± 9.128.3 ± 9.627.2 ± 9.3
Sex: Female, Male
Sex: Female, Male(Participants)TEZ/IVAVX-659/TEZ/IVA TCTotal
Female332659
Male242852
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)TEZ/IVAVX-659/TEZ/IVA TCTotal
Hispanic or Latino112
Not Hispanic or Latino5652108
Unknown or Not Reported011
Race (NIH/OMB)
Race (NIH/OMB)(Participants)TEZ/IVAVX-659/TEZ/IVA TCTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American000
White5654110
More than one race000
Unknown or Not Reported101
Forced Expiratory Volume in 1 Second (ppFEV1)
Forced Expiratory Volume in 1 Second (ppFEV1)(percentage points)TEZ/IVAVX-659/TEZ/IVA TCTotal
Mean62.9 ± 14.962.0 ± 14.862.4 ± 14.8
08

Study locations

46 sites
  • University of Alabama at Birmingham
    Birmingham, Alabama 35233, United States
  • Yale New Haven Medical Center
    New Haven, Connecticut 06511, United States
  • University of Miami/Miller School of Medicine
    Miami, Florida 33136, United States
  • St. Luke's CF Center of Idaho
    Boise, Idaho 83712, United States
  • Advocate Children's Hospital- Park Ridge/ North Suburban Pulmonary and Critical Care Consultants
    Niles, Illinois 60714, United States
  • Indiana Clinical Research Center, IU Health University Hospital
    Indianapolis, Indiana 46202, United States
  • The University of Iowa Hospitals and Clinics
    Iowa City, Iowa 52242, United States
  • The Johns Hopkins Hospital
    Baltimore, Maryland 21287, United States
  • Boston Children's Hospital
    Boston, Massachusetts 02115, United States
  • Helen DeVos Children's Hospital CF Center
    Grand Rapids, Michigan 49503, United States
  • Children's Mercy Hospital
    Kansas City, Missouri 64108, United States
  • Washington University School of Medicine / St. Louis Children's Hospital
    Saint Louis, Missouri 63110, United States
  • Rutgers-Robert Wood Johnson Medical School
    New Brunswick, New Jersey 08901, United States
  • Albany Medical College
    Albany, New York 12208, United States
  • Northwell Health, Long Island Jewish Medical Center
    New Hyde Park, New York 11040, United States
  • Columbia University Medical Center
    New York, New York 10032, United States
  • SUNY Upstate Medical University
    Syracuse, New York 13210, United States
  • Cincinnati Children's Hospital Medical Center
    Cincinnati, Ohio 45229, United States
  • Respiratory Diseases of Children and Adolescents
    Oklahoma City, Oklahoma 73211, United States
  • Oregon Health & Science University
    Portland, Oregon 97239, United States
  • Children's Hospital of Pittsburgh of University of Pittsburgh Medical Center
    Pittsburgh, Pennsylvania 15224, United States
  • Sanford Research/ USD
    Sioux Falls, South Dakota 57105, United States
  • University of Tennessee Medical Center-Adult Cystic Fibrosis Clinic
    Knoxville, Tennessee 37920, United States
  • Children's Foundation Research Center/ Le Bonheur Children's Hospital
    Memphis, Tennessee 38103, United States
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37232, United States
  • Baylor College of Medicine
    Houston, Texas 77030, United States
  • University of Utah/ Primary Children's Medical Center
    Salt Lake City, Utah 84132, United States
  • Seattle Children's Hospital
    Seattle, Washington 98105, United States
  • The Alfred Hospital
    Melbourne, Victoria, Australia
  • Royal Adelaide Hospital
    Adelaide, Australia
  • Prince Charles Hospital
    Chermside, Australia
  • Institute for Respiratory Health Inc./ Sir Charles Gairdner Hospital
    Nedlands, Australia
  • John Hunter Hospital & Hunter Medical Research Institute
    New Lambton Heights, Australia
  • Charite Paediatric Pulmonology Department
    Berlin, Germany
  • Pneumologische Praxis Pasing
    Muenchen, Germany
  • Cork University Hospital
    Dublin, Ireland
  • Our Lady's Children's Hospital
    Dublin, Ireland
  • St. Vincent's University Hospital
    Dublin, Ireland
  • Hospital Universitari Vall d Hebron
    Barcelona, Spain
  • Hospital Universitari Vall d'Hebron Servicio de Broncoscopia
    Barcelona, Spain
  • Hospital Universitario Virgen del Rocio
    Sevilla, Spain
  • Papworth Hospital NHS Foundation Trust, Papworth Everard
    Cambridge, United Kingdom
  • Liverpool Heart and Chest Hospital
    Liverpool, United Kingdom
  • Royal Brompton & Harefield NHS Foundation Trust, Royal Brompton Hospital
    London, United Kingdom
  • Wythenshawe Hospital
    Manchester, United Kingdom
  • University Hospital Llandough
    Penarth, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2018 to primary completion in Sep 2018, 4 months.

Results were first posted in Oct 2019, 1 year after primary completion.

Of 58 industry-sponsored phase 3 interventional studies under Cystic Fibrosis, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 36. This study's 4 months is below that.

Counting every sponsor, half of 67 studies reached it within 26 months; a quarter within 16 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 1, 2018
First posted
Mar 9, 2018
StartActual
May 1, 2018
Primary completionActual
Sep 26, 2018
CompletionActual
Oct 8, 2018
Results first posted
Oct 17, 2019
Last update
Oct 17, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 17, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03460990
Responsible party
Sponsor
First posted
Mar 9, 2018
Start date
May 1, 2018
Primary completion
Sep 26, 2018
Completion
Oct 8, 2018
Results posted
Oct 17, 2019
Last update
Oct 17, 2019

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion